Authors

Latest:

Dr. Beitinjaneh on the Evaluation of Tabelecleucel in EBV+ Hematologic Malignancies

Amer M. Beitinjaneh, MD, discusses updated results from phase 3 ALLELE trial investigating the use of tabelecleucel in Epstein-Barr Virus–positive post-transplant lymphoproliferative disease following allogeneic hematopoietic stem cell transplant or solid organ transplant after failure of rituximab with or without chemotherapy.

Myriam Chalabi, MD

Latest:

Dr. Chalabi on the Role of MSI Testing in CRC

Myriam Chalabi, MD, discusses the utility of microsatellite instability (MSI) testing in colorectal cancer,

Girindra Raval, MD

Girindra Raval, MD, is an associate professor in the Department of Medicine: Hematology and Oncology at the Medical College of Georgia of Augusta University.

Latest:

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Travis J. Osterman, DO

Latest:

How to Make Clinical Decisions With AI in Oncology

Speculation on the impact of large language models or artificial intelligence in the future of health care is commonplace, causing excitement and concern.

Chih-Yi Liao, MD

Latest:

Dr Liao on the Value of Molecular Testing in Biliary Tract Carcinoma

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Jonathan Coggins, MHA

Latest:

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

Patricia Pautier, MD

Latest:

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in uterine and soft tissue leiomyosarcoma.

Benjamin Levy, MD

Latest:

Patient Selection and Sequencing of NSCLC ADCs

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Timothy J. Pluard, MD

Latest:

Beyond Hyperglycemia: Complete Safety Management for PI3K Inhibitor Combinations

Panelists discuss how to manage PIK3CA inhibitor toxicities through frequent early monitoring, patient education about warning signs, use of continuous glucose monitors (CGMs) when needed, and willingness to interrupt treatment and reduce doses while maintaining patients on therapy long term.

Michael Cecchini, MD

Michael Cecchini, MD, is an associate professor of medicine (medical oncology) at Yale School of Medicine; as well as the co-director of the Colorectal Program in the Center for Gastrointestinal (GI) Cancers, the medical oncology section lead for the National Accreditation Program for Rectal Cancer, the co-director of the GI Clinical Research Team, and a phase 1 investigator at Yale Cancer Center

Latest:

Dr Cecchini on the Efficacy of Neoadjuvant Chemotherapy in CRC Liver Metastases

Michael Cecchini, MD, discusses the effects of neoadjuvant chemotherapy on tumor-infiltrating lymphocyte levels in colorectal cancer with liver metastases.

Jason Zhu, MD

Latest:

Dr. Zhu on Treatment Strategies for Node-Positive Prostate Cancer

Jason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.

Jonathan Spicer, MD, PhD

Latest:

Dr Spicer on Surgical Considerations After Approval of Perioperative Nivolumab in Resectable NSCLC

Jonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.

David B. Zhen, MD

Latest:

Immunotherapy's Effect on the Upper GI Cancer Treatment Paradigm

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

Joshi Alumkal, MD

Latest:

Dr Alumkal on Standard Treatment Options For Patients With HRD-Altered mCRPC

Joshi Alumkal, MD, discusses treatment options for patients with metastatic castrate-resistant prostate cancer harboring homologous recombination deficient alterations, including PARP inhibitors.

Daniel Rotroff, PhD

Latest:

Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast Cancer

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

Andrew Lim, MD

Andrew Lim, MD, is a radiation oncologist with Keck Medicine of USC.

Latest:

Moving the Needle in Undifferentiated Pleomorphic Sarcoma: Conclusions

In this episode, experts highlight the key takeaways from the Stand Up to Cancer SARC 032 study and its clinical implications.

Rita Assi, MD

Latest:

The Future of CAR T-Cell Therapy in R/R DLBCL: Closing Reflections and Key Takeaways

Experts discuss the future outlook for chimeric antigen receptor T-cell therapy (CAR T) in diffuse large B-cell therapy (DLBCL), exploring potential advancements and evolving treatment strategies.

LSU LCMC Health Cancer Center

Latest:

IIT Madras partners with LSU Health New Orleans, US, to Accelerate Global Health Innovation

The collaboration blends LSU Health New Orleans’s robust research capabilities with IIT Madras’ technology innovation to drive global health impact.

Mostafa Nasr, PhD candidate, Moffitt Cancer Center

Latest:

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Katherine C. Ansley, MD

Katherine C. Ansley, MD, is an associate professor in the Section of Hematology and Oncology in the Department of Internal Medicine at Wake Forest University School of Medicine and a breast cancer leader at Atrium Health Wake Forest Baptist Hematology and Oncology - Cancer Center.

Latest:

Dr Ansley on the Role of Elacestrant in ER+/HER2– Advanced Breast Cancer

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.